DXVX Supplies GenomeCheck Genomic Analysis Service to Malaysia

DXVX announced on the 27th that it has signed a supply contract with MGRC Therapeutics, a subsidiary of the Malaysian Genomics Resource Center (MGRC), to provide genome analysis services, GenomeCheck, to the Malaysian market.

MGRC, established in 2010 and listed on the Malaysian stock exchange, has four subsidiaries including MGRC Therapeutics, MGRC Healthcare, MGRC Biopharma, and Malaysia Genomics & Life Sciences. Through this supply contract, DXVX's GenomeCheck service will be supplied to local hospitals and clinics in Malaysia by leveraging MGRC's network.

DXVX explained that this contract marks the first step in targeting the Southeast Asian market, including Malaysia. The company plans to discuss various cooperation methods to expand service supply in other business areas such as in vitro diagnostics and digital healthcare.

GenomeCheck is a service that enables non-invasive prenatal genetic testing for mothers and fetuses, as well as newborn genetic testing. The company attributes the success of this contract to the service's excellence, including the number of diseases that can be tested, high accuracy, and short testing periods. With this Malaysian contract, DXVX expects to expand its market from Northeast Asia to Southeast Asia and secure a leading position in the global medical market.

Azri Azrai, Chairman of MGRC, said, "We are very pleased to sign this contract," and added, "We will seek more cooperation with DXVX in the fields of in vitro diagnostics and digital healthcare." Kwon Kyu-chan, CEO of DXVX, also stated, "Malaysia is a very important business hub in Southeast Asia," and added, "Starting with this contract, we will strive to expand the distribution of genome analysis services throughout Southeast Asia."